Cancer care is expensive for reasons that can each be named, and most of them have a fix that is already working somewhere. This page pairs 11 cost drivers with 30 things already being done (each with its year and source) and 29 ideas that could do more, 15 of them already being tested at scale. Every idea says who would have to act, roughly what it costs to try and how long until the first evidence.
Savings figures are quoted only as the cited report states them. Lower-dose and shorter-course regimens are listed where a randomised trial found them non-inferior; they are options to raise with the treating team, not instructions. For help with a bill today, start with the financial help browser (manufacturer, charity and public programmes by country and product) and the plan rankings.
Manufacturers set US launch prices freely and have raised them annually; coinsurance is a percentage of the list price, so the patient's bill rises with it even when the plan negotiates rebates.
Bottleneck: Prices and value, Incentives reward me-too drugs and marginal gains
Further reading: CMS: selected drugs and negotiated prices (2026 and 2027) · ESMO Magnitude of Clinical Benefit Scale · Institute for Clinical and Economic Review · NHS England: Cancer Drugs Fund.
A drug that adds a year of life in one cancer and six weeks in another sells at the same price for both; indication-specific prices would pay for the benefit actually delivered.
ESMO Magnitude of Clinical Benefit Scale · ASCO Value Framework update (JCO 2016)
Since 2023 manufacturers must rebate Medicare when a drug's price rises faster than inflation; applying the same rule to commercial plans would end the yearly list-price rises that drive coinsurance up.
Oncology has two respected scales that grade how much a drug helps in each indication; payers could set low copays for high-grade uses and require a conversation for low-grade ones instead of blanket prior authorisation.
Since 2016 England's Cancer Drugs Fund has paid a confidential discounted price for cancer drugs whose benefit is plausible but unproven, collected outcome data for two or three years, then had NICE decide for good; most drugs that entered were later recommended. Other systems could use the same managed-access deal instead of a yes-or-no at launch.
The same infusion costs more in a hospital outpatient department than in a clinic, and Medicare's Part B add-on is a percentage of price. Hospitals in the 340B programme buy at deep discounts but bill at full price, and the GAO found they prescribed more and dearer Part B drugs than other hospitals.
Bottleneck: Prices and value, Incentives reward me-too drugs and marginal gains, Fragmented care and guideline gaps
The same chemotherapy infusion costs payers and patients more in a hospital outpatient department than in a doctor's office; paying one rate would stop hospitals buying clinics to charge the higher price.
Medicare pays clinics the drug's average sales price plus 6%, so a dearer drug earns the clinic more; replacing the percentage with a flat handling fee removes the incentive to pick the expensive option.
CMS: Part B drug payment (ASP pricing files) · MedPAC reports to Congress
Hospitals in the 340B programme buy cancer drugs at steep discounts but usually bill patients and insurers the full price; requiring the discount to reach low-income patients would turn a hospital subsidy into patient relief.
HRSA: 340B Drug Pricing Program · GAO-15-442: Medicare Part B drugs and 340B hospitals (2015)
Copies of trastuzumab, bevacizumab, rituximab and pegfilgrastim are approved and cheaper, but the switch depends on the prescriber, the payer's preference and the purchasing contract lining up, and percentage-based payment rewards the dearer product.
Bottleneck: Prices and value, Knowledge reaches practice too slowly
Copies of the big antibody drugs are approved and cheaper, but uptake depends on each prescriber; letting the pharmacy substitute the biosimilar unless the oncologist objects would move most patients within a year.
IQVIA Institute: Biosimilars in the United States 2023-2027 (January 2023) · FDA: Biosimilars
US law lets a pharmacist swap an 'interchangeable' biosimilar without asking the prescriber, but earning that label used to need costly switching studies; the FDA now says those are usually unnecessary, which should be made permanent for cancer antibodies.
Medicare pays clinics the drug's average sales price plus 6%, so a dearer drug earns the clinic more; replacing the percentage with a flat handling fee removes the incentive to pick the expensive option.
CMS: Part B drug payment (ASP pricing files) · MedPAC reports to Congress
Old cytotoxics cost a few dollars a dose and run short because margins are thin; old oral drugs such as imatinib and abiraterone are cheap to buy yet can carry high specialty-tier coinsurance through insurance.
Bottleneck: Prices and value, Most of the world has almost no cancer care, No incentive to repurpose cheap drugs
Further reading: Intellectual Property India: compulsory licence order, Natco v Bayer (2012) · PAHO Strategic Fund.
Generic imatinib and abiraterone can cost patients hundreds of dollars a month through insurance yet be sold at cost plus a fixed markup by transparent pharmacies; making that the default channel for oral cancer generics would save patients and plans money.
Cisplatin and carboplatin cost a few dollars a dose yet ran short across the US in 2023 because too few makers found them worth producing; a non-profit maker with long-term hospital contracts would keep them on the shelf.
Small countries pay more for the same generic chemotherapy because they buy alone; the PAHO Strategic Fund and the WHO essential medicines list show that buying together brings prices down and keeps supply steady.
WHO Model Lists of Essential Medicines · PAHO Strategic Fund
India's 2012 compulsory licence on sorafenib cut its price by about 97% and its 2019 cap on trade margins lowered the shelf price of 42 cancer drugs; voluntary licences through a patent pool would achieve the same without a fight.
Medicines Patent Pool · National Pharmaceutical Pricing Authority (India) (archived copy) · Intellectual Property India
Most cancer drug doses came from the highest dose tolerated in early trials, and adjuvant durations were fixed without duration-finding studies. Lower doses, longer intervals and shorter courses have matched outcomes wherever they have been tested.
Bottleneck: Wrong doses, Surgery and radiotherapy cure most, get least, Toxicity and quality of life are undervalued
Taking 250 mg of abiraterone with a low-fat breakfast gives the same PSA response and testosterone suppression as the standard 1,000 mg fasting, because food increases absorption several-fold, so a quarter of the drug treats each man. The label still says fasting and no company promotes the food-effect dose, so adoption is patchy.
A randomised trial at Tata Memorial added nivolumab at 20 mg every three weeks, about one-twelfth of the standard dose, to cheap metronomic chemotherapy for head and neck cancer patients who could not afford full-dose immunotherapy, and they lived longer. Checkpoint inhibitors saturate their target far below approved doses, so publicly funded trials should test low doses in common cancers.
Patil et al., JCO 2023: low-dose nivolumab with metronomic chemotherapy
The FDA now requires new cancer drugs to prove their dose is the right one rather than the highest tolerated; asking the same question of the twenty best-selling approved drugs could cut doses, side effects and cost at once.
Pembrolizumab 400 mg every six weeks is approved and works like 200 mg every three weeks, and it halves the number of clinic visits, infusion chairs and travel days without changing the drug bill.
The PERSEPHONE trial showed six months of trastuzumab after surgery is as good as twelve, halving the drug cost; no company will run such trials, so public funders and charities must.
One week of breast radiotherapy in five doses works as well as three weeks in fifteen, but clinics paid per dose lose money by switching; paying one price per course removes the penalty.
Under-the-skin versions of atezolizumab, nivolumab and pembrolizumab take minutes rather than an hour and need no infusion chair, so they can be given by a nurse near home, cutting facility fees and travel.
Weight-based doses rarely match vial sizes, so the leftover is discarded and still billed; closed-system vial sharing and rounding doses to the nearest vial within 10% eliminate most of that waste.
CMS: Discarded drug refunds (JW and JZ modifiers) (page moved; nearest live section)
Oral cancer drugs sit on the pharmacy benefit with percentage coinsurance on a specialty tier; infused drugs sit on the medical benefit with a copay. Self-funded employer plans are exempt from state parity laws.
Bottleneck: Prices and value, Regulatory divergence between regions
Most states require insurers to charge no more for a cancer pill than for an infusion, but the law does not reach the self-funded employer plans that cover most working Americans; a federal rule would close the gap.
Congress.gov: Cancer Drug Parity Act, H.R. 1730 (118th Congress)
Generic imatinib and abiraterone can cost patients hundreds of dollars a month through insurance yet be sold at cost plus a fixed markup by transparent pharmacies; making that the default channel for oral cancer generics would save patients and plans money.
Oral cancer drugs under Part D now have a yearly cap of $2,100, but infused drugs under Part B still carry 20% coinsurance with no limit; a Part B cap would close the biggest hole left in Medicare cancer coverage.
Bills, lost earnings and travel push people into debt, and people in debt skip doses and appointments. It is a treatment side effect with its own dose-response.
Bottleneck: Toxicity and quality of life are undervalued, Patients lack understanding, navigation and agency
People with cancer are far more likely to go bankrupt than people without, and the ones who do have worse survival; a two-question screen at diagnosis plus a financial navigator catches the problem while it can still be fixed.
Ramsey et al., Health Affairs 2013: Washington State cancer patients and bankruptcy · OnCo financial help browser
Oral cancer drugs under Part D now have a yearly cap of $2,100, but infused drugs under Part B still carry 20% coinsurance with no limit; a Part B cap would close the biggest hole left in Medicare cancer coverage.
Most states require insurers to charge no more for a cancer pill than for an infusion, but the law does not reach the self-funded employer plans that cover most working Americans; a federal rule would close the gap.
Congress.gov: Cancer Drug Parity Act, H.R. 1730 (118th Congress)
Journeys to a distant centre, parking, hotels and days off work are real costs that no claims database records; for rural and low-income families they decide whether treatment is completed.
Bottleneck: Fragmented care and guideline gaps, Most of the world has almost no cancer care
Travel and time off work are among the biggest costs families face; if consultations happen by video, blood tests locally and oral drugs by mail, most routine visits need no journey at all.
Pembrolizumab 400 mg every six weeks is approved and works like 200 mg every three weeks, and it halves the number of clinic visits, infusion chairs and travel days without changing the drug bill.
Under-the-skin versions of atezolizumab, nivolumab and pembrolizumab take minutes rather than an hour and need no infusion chair, so they can be given by a nurse near home, cutting facility fees and travel.
One week of breast radiotherapy in five doses works as well as three weeks in fifteen, but clinics paid per dose lose money by switching; paying one price per course removes the penalty.
Chemotherapy in the final two weeks, late intensive-care admissions and late hospice referral are expensive, rarely help, and are what most patients say they do not want when asked early enough.
Bottleneck: Pain relief and palliative care are unavailable to most, Toxicity and quality of life are undervalued
Chemotherapy in the last two weeks of life rarely helps and costs a great deal; patients who have an early conversation about what matters to them choose it less often and live at least as long.
In a trial the investigational drug is supplied free, and public and private payers are required to cover routine costs; enrolment lowers the bill for the patient and the payer while producing the evidence everyone needs.
Bottleneck: Trials enrol too few, too slowly, Prices and value
In a clinical trial the experimental drug is free to the patient and the payer, and since 2022 Medicaid must cover routine trial costs like Medicare and private plans do; pointing more patients to trials lowers bills as well as advancing science.
Medicaid.gov: coverage of routine patient costs in clinical trials (Clinical Treatment Act) · Medicare.gov: Clinical research studies
The PERSEPHONE trial showed six months of trastuzumab after surgery is as good as twelve, halving the drug cost; no company will run such trials, so public funders and charities must.
A randomised trial at Tata Memorial added nivolumab at 20 mg every three weeks, about one-twelfth of the standard dose, to cheap metronomic chemotherapy for head and neck cancer patients who could not afford full-dose immunotherapy, and they lived longer. Checkpoint inhibitors saturate their target far below approved doses, so publicly funded trials should test low doses in common cancers.
Patil et al., JCO 2023: low-dose nivolumab with metronomic chemotherapy
Every idea has its own page with hypothesis, rationale, the test that would confirm or kill it, and the bottlenecks it attacks. Vote or argue on the idea page; suggest a new one through the issue form.